Table 2.
Authors | Journal | Cases | Primary endpoint | Conclusion |
---|---|---|---|---|
COREAN trial |
Lancet Oncol (2014) | 869 | ||
Open 170 | 3 y‐DFS | Proved non‐inferiority of Lap | ||
Lap 170 | ||||
COLOR‐II trial |
N Eng J Med (2015) | 794 | 3 y‐local recurrence free survival rate | Proved non‐inferiority of Lap |
Open 345 | ||||
Lap 699 | ||||
ACOSOG‐Z6051 trial |
JAMA (2015) | 462 | Successful resection rate (CRM, DM, TME) | Not proved non‐inferiority of Lap |
Open 222 | ||||
Lap 240 | ||||
ALaCaRT trial Ref. 34 |
JAMA (2015) | 473 | Successful resection rate (CRM, DM, TME) | Not proved non‐inferiority of Lap |
Open 235 | ||||
Lap 238 |